ConductScience.org, home

Paper41890397

Efficient Synthesis of Enlicitide Chloride through Convergent Solution-Phase and Hybrid Solution-Solid-Phase Strategies.

Zhao X and 5 others. Precis Chem, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Efficient Synthesis of Enlicitide Chloride through Convergent Solution-Phase and Hybrid Solution-Solid-Phase Strategies. Papers, record 41890397. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41890397

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Efficient Synthesis of Enlicitide Chloride through Convergent Solution-Phase and Hybrid Solution-Solid-Phase Strategies.
PubMed
Journal
Precis Chem
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhao XXuting
2Li XXinqi
3Zhang SShuxian
4Song WWeiguo
5Fang HHaohttps://orcid.org/0000-0002-2879-5146
6Jin KKanghttps://orcid.org/0000-0002-4026-0128

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References25

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127854420Heart Disease and Cancer Deaths - Trends and Projections in the United States, 1969-2020.Prev Chronic Dis2016https://conductscience.org/library/papers/27854420PubMed
230448414Small molecules as inhibitors of PCSK9: Current status and future challenges.Eur J Med Chem2019https://conductscience.org/library/papers/30448414PubMed
325825402Cardiology patient page. Statin intolerance.Circulation2015https://conductscience.org/library/papers/25825402PubMed
433536635Trends in peptide drug discovery.Nat Rev Drug Discov2021https://conductscience.org/library/papers/33536635PubMed
534704436A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors.J Med Chem2021https://conductscience.org/library/papers/34704436PubMed
640123407Total Synthesis of Enlicitide Decanoate.J Am Chem Soc2025https://conductscience.org/library/papers/40123407PubMed
736446632Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment.J Med Chem2022https://conductscience.org/library/papers/36446632PubMed
835121175Development of small-molecule PCSK9 inhibitors for the treatment of hypercholesterolemia.Drug Discov Today2022https://conductscience.org/library/papers/35121175PubMed
937125593Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor.Circulation2023https://conductscience.org/library/papers/37125593PubMed
10308793552019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Circulation2019https://conductscience.org/library/papers/30879355PubMed
1128970592A Therapeutic Peptide Vaccine Against PCSK9.Sci Rep2017https://conductscience.org/library/papers/28970592PubMed
1229438441Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin/kexin type 9 (PCSK9) epitope in mice.PLoS One2018https://conductscience.org/library/papers/29438441PubMed
1331599007A gold mine for drug discovery: Strategies to develop cyclic peptides into therapies.Med Res Rev2020https://conductscience.org/library/papers/31599007PubMed
1425773378Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.N Engl J Med2015https://conductscience.org/library/papers/25773378PubMed
1536889610Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616.J Am Coll Cardiol2023https://conductscience.org/library/papers/36889610PubMed
1634246818The emerging landscape of peptide-based inhibitors of PCSK9.Atherosclerosis2021https://conductscience.org/library/papers/34246818PubMed
1727959715A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.N Engl J Med2017https://conductscience.org/library/papers/27959715PubMed
1831784033The changing landscape of lipid-lowering therapy after the new ESC/EAS guidelines for the management of dyslipidaemias: Launching the era of triple hypolipidaemic therapy in very high risk patients.Atherosclerosis2020https://conductscience.org/library/papers/31784033PubMed
1919930098The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis.J Intern Med2009https://conductscience.org/library/papers/19930098PubMed
2023485362Gene silencing approaches for the management of dyslipidaemia.Trends Pharmacol Sci2013https://conductscience.org/library/papers/23485362PubMed

See all 25 referencesDownload CSV of references

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
LDLR3949PubTator's text mininghttps://conductscience.org/library/genes/3949NCBI Gene
PCSK9255738PubTator's text mininghttps://conductscience.org/library/genes/255738NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41890397

GET https://conductscience.org/api/papers/v1/41890397/references?page=2